Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SANDRIL vs UNITENSEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sandril (reserpine) acts by depleting catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve terminals via irreversible inhibition of the vesicular monoamine transporter (VMAT). This leads to reduced sympathetic output, decreased peripheral vascular resistance, and lowered blood pressure.
Direct-acting vasodilator that relaxes arteriolar smooth muscle, reducing peripheral vascular resistance and lowering blood pressure. The exact mechanism is unclear but may involve interference with calcium influx across vascular smooth muscle cell membranes.
Hypertension (mild to moderate),Management of psychotic disorders (off-label)
Hypertension (alone or in combination with other antihypertensives)
Initial: 2 mg orally twice daily; increase by 2 mg/day every 1-2 weeks; usual maintenance: 4-16 mg/day in 2 divided doses; maximum: 16 mg/day.
Oral: 2.5 mg once daily, may increase to 5 mg once daily after 2 weeks if needed.
Terminal elimination half-life is 3-5 hours in adults; prolonged to 8-15 hours in elderly or renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 12-15 hours; prolonged in renal impairment (up to 35 hours).
Primarily metabolized by the liver via hydrolysis and conjugation; major metabolites include reserpic acid and methyl reserpate. CYP450 enzymes are not significantly involved.
Extensively metabolized in the liver via N-acetylation (polymorphic NAT2 enzyme) and hydroxylation, followed by glucuronidation. Citrulline is a minor metabolite. Oral bioavailability is increased in slow acetylators.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (20-30%); biliary/fecal excretion accounts for <10%.
Primarily renal (40-60% unchanged drug), biliary/fecal (20-30% as metabolites).
Approximately 95% bound to albumin and alpha-1-acid glycoprotein.
85-95% bound primarily to albumin.
3-5 L/kg, indicating extensive tissue distribution.
0.3-0.5 L/kg, indicating distribution mainly in extracellular fluid.
Oral bioavailability is 50-70% due to first-pass metabolism.
Oral: 70-85% due to first-pass metabolism.
GFR 30-89 m L/min: no adjustment needed; GFR <30 m L/min: reduce dose by 50%; hemodialysis: administer after dialysis; peritoneal dialysis: avoid use.
GFR 30-89 m L/min: 2.5 mg once daily; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: 2.5 mg once daily; Child-Pugh B or C: not recommended.
Children 6-12 years: initial 0.5 mg/kg/day orally in 2 divided doses; increase by 0.5 mg/kg/day every 2 weeks; maximum 3 mg/kg/day up to 16 mg/day. Children >12 years: same as adult dosing.
Not established; safety and efficacy in pediatric patients have not been studied.
Initial dose 1 mg orally twice daily; titrate slowly; maximum 8 mg/day; monitor for hypotension and sedation.
Start at 2.5 mg once daily; titrate cautiously due to increased sensitivity and renal impairment.
WARNING: Risk of Suicide – Reserpine may cause severe depression and suicidal ideation. Use with caution in patients with a history of depression. Discontinue if signs of depression occur.
Lupus-like syndrome: Use of hydralazine, the active component of Unitensen, has been associated with a drug-induced lupus erythematosus-like syndrome, particularly in slow acetylators and at higher doses. Symptoms include arthralgia, myalgia, rash, fever, and serositis. Discontinue hydralazine if lupus-like symptoms develop.
May cause mental depression, peptic ulcer activation (due to increased gastric acid secretion), and extrapyramidal symptoms. Avoid in patients with a history of depression, Parkinson's disease, or epilepsy. Monitor for hypotension, bradycardia, and electrolyte disturbances. Taper gradually to avoid withdrawal symptoms (e.g., severe hypertension).
May cause a lupus-like syndrome, especially in slow acetylators; monitor for symptoms. Can precipitate angina or myocardial infarction in patients with coronary artery disease due to reflex tachycardia. Use with caution in patients with cerebrovascular disease, severe renal impairment, or pre-existing hypotension. Hematologic adverse effects (e.g., neutropenia, agranulocytosis) have been reported rarely; monitor CBC periodically. Peripheral neuritis may occur (possibly due to pyridoxine deficiency).
Hypersensitivity to reserpine, history of mental depression (especially with suicidal tendencies), active peptic ulcer, ulcerative colitis, electroconvulsive therapy (ECT), and concurrent use with MAO inhibitors.
Hypersensitivity to hydralazine or any component of the formulation; coronary artery disease (due to risk of reflex tachycardia and myocardial ischemia); mitral valvular rheumatic heart disease (may increase pulmonary artery pressure).
Avoid excessive intake of potassium-rich foods (bananas, oranges, spinach) unless directed by prescriber. May increase alcohol-induced hypotensive effects. Caffeine may enhance diuretic effect. Grapefruit juice has not been reported to interact, but caution with high-sodium foods as they may reduce antihypertensive efficacy.
Avoid grapefruit juice as it may increase drug levels. Limit alcohol intake due to additive hypotensive effects. No specific food restrictions otherwise.
FDA Pregnancy Category D. First trimester: limb reduction defects, cardiac anomalies, neural tube defects. Second/third trimesters: fetal growth restriction, oligohydramnios, preterm labor. Neonatal: withdrawal syndrome, respiratory depression.
First trimester: Risk of congenital malformations based on animal studies; limited human data suggest possible association with fetal anomalies. Second and third trimesters: Fetal hypotension, renal impairment, oligohydramnios, and skull ossification defects.
Contraindicated due to neonatal sedation and withdrawal risk. M/P ratio not established; excreted in breast milk at concentrations 50-100% of maternal serum.
Excreted in human milk; M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects in the infant, including hypotension and renal impairment.
Dose reduction of 25-50% recommended in the third trimester due to increased volume of distribution and reduced hepatic clearance; avoid use during labor due to respiratory depression risk.
Increased volume of distribution and renal clearance in pregnancy may require dose increase; however, limited data. Avoid use in pregnancy unless no alternative.
SANDRIL is a brand name for hydrochlorothiazide, a thiazide diuretic. Monitor serum potassium and magnesium levels, as hypokalemia and hypomagnesemia are common. Avoid use in patients with anuria or sulfonamide allergy. Start at low dose (12.5-25 mg daily) to minimize electrolyte disturbances. Onset of action is 2 hours, peak 4-6 hours, duration 6-12 hours. Use caution in patients with renal impairment (Cr Cl <30 m L/min is contraindicated).
Unitensen (cryptenamine tannate) is a veratrum alkaloid used historically for hypertension. Monitor for bradycardia, hypotension, and emesis; dose titration is critical. Avoid in patients with coronary insufficiency or recent MI. Onset is rapid, and effects are dose-dependent.
Take this medication exactly as prescribed, usually in the morning to avoid nighttime urination.,Avoid prolonged sun exposure; use sunscreen as this drug may increase sensitivity to sunlight.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst, or confusion.,Do not take with other medications that lower blood pressure without consulting your doctor.,This drug may increase blood sugar and uric acid levels; monitor if diabetic or gout-prone.
Take this medication exactly as prescribed; do not increase the dose without consulting your doctor.,Report any severe nausea, vomiting, or dizziness immediately, as these may indicate overdose.,Avoid alcohol and grapefruit juice, as they may enhance hypotensive effects.,Rise slowly from sitting or lying positions to prevent fainting.,Keep a record of your blood pressure and heart rate to share with your healthcare provider.
No interactions on record
No interactions on record
Common clinical questions about SANDRIL vs UNITENSEN, answered by our medical review team.
SANDRIL is a Rauwolfia Alkaloid Antihypertensive that works by Sandril (reserpine) acts by depleting catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve terminals via irreversible inhibition of the vesicular monoamine transporter (VMAT). This leads to reduced sympathetic output, decreased peripheral vascular resistance, and lowered blood pressure.. UNITENSEN is a Rauwolfia Alkaloid Antihypertensive that works by Direct-acting vasodilator that relaxes arteriolar smooth muscle, reducing peripheral vascular resistance and lowering blood pressure. The exact mechanism is unclear but may involve interference with calcium influx across vascular smooth muscle cell membranes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SANDRIL and UNITENSEN depend on the specific clinical indication. These are both Rauwolfia Alkaloid Antihypertensive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SANDRIL is: Initial: 2 mg orally twice daily; increase by 2 mg/day every 1-2 weeks; usual maintenance: 4-16 mg/day in 2 divided doses; maximum: 16 mg/day.. The standard adult dose of UNITENSEN is: Oral: 2.5 mg once daily, may increase to 5 mg once daily after 2 weeks if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SANDRIL and UNITENSEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SANDRIL is classified as Category C. FDA Pregnancy Category D. First trimester: limb reduction defects, cardiac anomalies, neural tube defects. Second/third trimesters: fetal growth restriction, oligohydramnios, prete. UNITENSEN is classified as Category C. First trimester: Risk of congenital malformations based on animal studies; limited human data suggest possible association with fetal anomalies. Second and third trimesters: Fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.